Background. Multidrug-resistant (MDR) tuberculosis in children is frequently associated with delayed diagnosis and treatment. There is limited evidence regarding the management and outcome of children with MDR-tuberculosis.
Methods. All children ,15 years of age with a diagnosis of culture-confirmed MDR-tuberculosis were included in this retrospective cohort study from 1 January 2003 to 31 December 2008, with follow-up documented until 31 May 2011. We identified children from Brooklyn Hospital for Chest Diseases and Tygerberg Children's Hospital, Western Cape Province, South Africa. Treatment outcomes were defined as 2-month sputum-culture conversion, treatment episode outcome, and survival.
Results. A total of 111 children (median age, 50 months) were included. The diagnosis was delayed in children who had no identified MDR-tuberculosis index case (median delay, 123 vs 58 days; P , .001). Sixty-two percent of patients (53 of 85) were sputum-smear positive, and 43% of patients (43 of 100) were human immunodeficiency virus (HIV) infected. Overall, 82% had favorable treatment outcomes; total mortality was 12%. Malnutrition was associated with failure to culture-convert at 2 months (odds ratio [ Conclusions. Despite advanced disease at presentation and a high prevalence of human immunodeficiency virus coinfection, children with MDR-tuberculosis can be treated successfully, using individualized treatment under routine conditions.
Multidrug-resistant (MDR) tuberculosis is caused by
Mycobacterium tuberculosis resistant to isoniazid and rifampin. The World Health Organization (WHO) estimated that there were 440 000 new MDR-tuberculosis cases worldwide during 2008 [1] . Treatment outcomes are generally poor in adults, with favorable outcomes reported in only 60% of those receiving treatment [2] . Even though childhood tuberculosis makes up 15%-20% of the global tuberculosis burden [3] , MDR-tuberculosis is poorly studied in children, the literature including mainly case reports or small case series [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
The diagnosis of tuberculosis in young children is challenging and often delayed [17] . Symptoms and signs may be nonspecific, especially in children ,3 years of age and in children infected with human immunodeficiency virus (HIV) [18] . Because of the paucibacillary nature of childhood tuberculosis, a microbiological diagnosis is typically made in only 20%-40% of cases with radiological evidence of intrathoracic disease [19] . Because drug susceptibility testing (DST) is only possible following bacteriological confirmation, confirmed MDR-tuberculosis in children is infrequent. In the absence of a known MDR-tuberculosis source case, children are often initially treated for drug-susceptible tuberculosis, with MDR-tuberculosis treatment started only once treatment is failing, microbiological and DST results become available, or an MDR-tuberculosis source case is identified.
Treating children with MDR-tuberculosis is complex. Few of the multiple drugs routinely used to treat MDR-tuberculosis have been studied in children, and guidance on drug regimens, dosages, appropriate monitoring, and duration of therapy is frequently extrapolated from adult data. As young children metabolize drugs more rapidly than adults and generally have paucibacillary disease [20] , this may not always be appropriate. We describe the clinical presentation, treatment, and outcome for a large cohort of children with confirmed MDR-tuberculosis and evaluate factors influencing treatment response.
METHODS

Setting and Population
This retrospective cohort study was conducted in Western Cape Province, South Africa, where the tuberculosis notification rate was 978 per 100 000 population in 2009 [21] . Among all children with routinely diagnosed culture-confirmed tuberculosis at Tygerberg Children's Hospital (TCH) during 2005-2007, tuberculosis in 6.7% was identified as MDR [22] . In this setting, children initially present to a variety of regional primary (ie, community-based) health clinics and referral hospitals, while TCH serves as the main referral center for children with drugresistant tuberculosis exposure or disease. Once children are stable during treatment, they are managed at the Brooklyn Hospital for Chest Diseases, a specialist tuberculosis hospital. After discharge, children are routinely followed as outpatients at TCH.
Eligibility Criteria
Children ,15 years of age were included if they received a diagnosis of confirmed MDR-tuberculosis between 1 January 2003 and 31 December 2008. DST for all children with cultureconfirmed tuberculosis was routine during the study period. Follow-up was documented until 31 May 2011.
Mycobacterial Culture and Drug Susceptibility Testing
Mycobacterial culture was completed at the accredited National Health Systems Reference Laboratory following a standard protocol to prevent mycobacterial cross-contamination. Primary mycobacterial cultures were established by inoculation of routine clinical samples into Middlebrook 7H9 broth-based Mycobacterial Growth Indicator Tubes (MGIT960; Becton Dickinson) following a standard protocol for decontamination, while lymph node aspirates, pleural fluid, cerebrospinal fluid, and other bodily fluids were directly inoculated. M. tuberculosis complex isolates were confirmed through polymerase chain reaction (PCR) [23] . Phenotypic DST was performed using 2 different assays that have been shown to yield highly concordant results, as previously described [24] .
Definition of Tuberculosis Episodes and Treatment Delay
A previous tuberculosis episode was defined as standard tuberculosis treatment (ie, isoniazid, rifampin, and pyrazinamide, with or without ethambutol) for at least 1 month, followed by a symptom-free period of $6 months (determined on the basis of reports by the parent/caregiver and the absence of presentations to any healthcare providers) before the start of the current MDR-tuberculosis episode; this is a commonly used programmatic definition of a separate episode [25] . An MDRtuberculosis episode was defined as beginning (if MDRtuberculosis was subsequently confirmed) at the child's initial documented presentation to the healthcare system, when the specimen was obtained confirming MDR-tuberculosis, or when tuberculosis treatment was commenced. Treatment delay was defined as the time from the start of the MDR-tuberculosis episode to the initiation of MDR-tuberculosis treatment. Treatment delay could not be determined for children who died or were lost to follow-up before the start of MDR-tuberculosis treatment or for those treated inadvertently with first-line drugs only.
Clinical Data and Standard of Care
MDR-tuberculosis treatment was based on the local standard of care, informed by international recommendations and available literature [26] [27] [28] [29] [30] [31] [32] [33] . High-dose isoniazid (15-20 mg/ kg) was used in the majority of cases, as there is evidence that isolates with an inhA promoter region mutation usually have a low minimum inhibitory concentration [34] . An injectable agent, most frequently amikacin (15-30 mg/kg), was typically used for 6 months; capreomycin (15-30 mg/kg) was substituted if resistance to amikacin was detected. Ofloxacin (15-20 mg/kg), the most effective fluoroquinolone available in the South African National Tuberculosis Control Programme, was used. Further drugs were added to result in at least 4 effective drugs. These included ethionamide (15-20 mg/kg), para-aminosalicylic acid (150 mg/kg), terizidone (10-20 mg/kg), amoxicillin/clavulanic acid (10-15 mg/kg every 8 hours), clarithromycin (7.5-15 mg/kg every 12 hours), and linezolid (10 mg/kg every 12 hours). All anti-tuberculosis drugs were given as directly observed therapy for the full treatment duration. Most children remained hospitalized during the intensive phase, when an injectable agent was given. Thereafter, children were treated at their local tuberculosis clinic, with hospital outpatient follow-up every 2 months. Children with extensively drug-resistant tuberculosis (XDR-tuberculosis; defined as MDR-tuberculosis with resistance to a fluoroquinolone and a second-line injectable agent) were treated for longer periods, typically 24 months. If an HIVinfected child was not yet receiving combination antiretroviral therapy (cART), cART was started after the initiation of MDR-tuberculosis treatment, consistent with national guidelines.
Clinical Data Collection
Data were collected through chart review. HIV testing was performed after written informed consent was obtained from the parent or legal guardian, with pretest and posttest counseling; an enzyme-linked immunosorbent assay was used for children aged .18 months, and a DNA PCR test was used for younger and breastfed children. Immunological staging in HIV-infected children used the WHO classification [35] . Weight was recorded and plotted on the National Center for Health Statistics weight-for-age percentile chart. Malnutrition was classified as a weight of less than the third percentile for age. Two tuberculin units were injected intradermally (purified protein derivative RT23; Statens Serum Institut) for tuberculin skin testing. Results were read at 48-72 hours, with transverse diameters of $10 mm and $5 mm considered positive in HIV-uninfected children and HIV-infected children, respectively. Tuberculosis severity was defined using chest radiographic features following review by a single expert reader, who read radiographs systematically with standardized recording [36] . Disease was classified as pulmonary if there were any chest radiographic changes attributable to tuberculosis or if any thoracic samples were positive for M. tuberculosis. Extrapulmonary disease was classified if any imaging (ie, ultrasonography, plain film radiology, or computed tomography) demonstrated extrathoracic tuberculosis or if a microbiological sample confirmed tuberculosis at a site other than the lungs. Intrathoracic radiological features were classified as nonsevere (ie, normal, hilar lymphadenopathy, airway compression, lobar/segmental collapse/opacification, or pleural effusions) and severe (ie, cavities, miliary opacification, or a widespread bronchopneumonic picture).
Outcome
Respiratory samples in children with pulmonary involvement were obtained monthly to monitor response to therapy. Standard international definitions of final treatment outcome were used, with minor adaption for children [37] . The definition of cure for adults with MDR-tuberculosis is completion of treatment with 5 cultures with negative results in the final 12 months of treatment [26] . For children with drug-susceptible tuberculosis, cure is defined as being sputum culture or smear negative in the last month of treatment and on $1 previous occasions [27] . Cure for this study was defined as negative results of 3 consecutive respiratory cultures obtained at least 1 month apart, with no positive culture results after the first negative result, in the presence of treatment completion. Treatment outcomes were further classified as favorable (ie, cured and treatment completed) or unfavorable (ie, died, lost to follow-up, treatment failure, or transferred out). For MDRtuberculosis episodes with positive results of an initial sputum culture, culture conversion was defined as the time from initiation of therapy until the first culture with negative results, provided there were no subsequent cultures with positive results and at least 2 further cultures with negative results. We describe 2-month culture conversion, as it is a frequently used surrogate marker for final treatment outcome in adult treatment trials [38] . We further describe the total proportion of children who died.
Statistical Analysis
Data were analyzed using Stata statistical software, version 11 (Stata). All identifier details were dissociated from clinical data by unique study numbers. Missing data were excluded from analysis. Continuous variables were used for age and delay. Of the 111 patients, 91 (82%) had a favorable treatment outcome. Of these, 3 were treated successfully with only firstline drugs: 2 had cervical lymph node disease and the other only hilar lymphadenopathy. Four patients were transferred to another hospital, and 3 were lost to follow-up. One adolescent, who received a diagnosis of pulmonary XDR-tuberculosis, was a repeat defaulter, and her sputum never converted. She was declared to have failed treatment after 2 years of intermittent treatment and eventually was transferred into adult care. One patient was still receiving treatment at the end of the study period, having been initially treated for MDR-tuberculosis with additional resistance to amikacin, according to his bacteriological data, and then for XDR-tuberculosis, based on his mother's bacteriological data. The overall mortality was 12% (13 deaths; Table 2 ), regardless of treatment initiation. Eleven children died during their MDR-tuberculosis episode, 1 was cured of tuberculosis but died in the year following the end of treatment, and 1 died following treatment failure.
Of the 88 patients successfully treated with MDR-tuberculosis drugs, 79 (89.8%) were alive and well 12 months after completion of treatment. Of the remaining 9 patients, 3 had been transferred to another institution, 5 had been lost to follow-up, and 1 had died. Those successfully treated were treated for a median duration of 18 months, including a median duration of 6 months with an injectable agent, with a median of 7 drugs over the total course of treatment (Table 3) .
Univariate analysis of clinical features and their association with outcome are shown in Table 4 . Malnutrition and severe chest radiographic changes were associated with a failure to culture-convert by month 2, unsuccessful treatment outcome, and death. HIV infection and extrapulmonary disease were associated with death. Children with positive smears at diagnosis were less likely to have culture-converted by month 2. Findings of multivariable analysis are shown in A total of 111 children were included in the study.
Abbreviations: F, female; HIV, human immunodeficiency virus; M, male; MDR-tuberculosis, multidrug-resistant tuberculosis; Neg, negative; Pos, positive; S. aureus, Staphylococcus aureus; XDR, extensively drug resistant.
(OR, 37.8 [95% CI, 2.78-513.4]; P 5 .006) all independently predicted mortality in a model that also adjusted for age.
DISCUSSION
We document the clinical presentation, treatment, and outcomes of children with culture-confirmed MDR-tuberculosis under routine clinical conditions in a setting where the tuberculosis burden is high. To our knowledge, this is the largest cohort of children with culture-confirmed MDR-tuberculosis described to date. Our data indicate that children with cultureproven MDR-tuberculosis tend to be young and malnourished, are frequently HIV-infected, and often present with radiological features of advanced disease. Furthermore, the absence of a known MDR-tuberculosis source case led to considerable delay in initiation of appropriate therapy. Treatment regimens were long (median duration, 18 months), with 6 months including an injectable agent. Of key importance is that, despite advanced disease and the presence of extrapulmonary disease in .30% of children, the majority were treated successfully, with .80% having favorable outcomes. We identified important risk factors for clinically and programmatically relevant treatment outcomes, including mortality. HIV infection, malnutrition, and extrapulmonary involvement were independent risk factors for death in adjusted analyses. Five of the 13 deaths occurred before MDR-tuberculosis was confirmed and appropriate treatment started, indicating the importance of early diagnosis. Although severe disease based on chest radiographic findings was associated with all outcome measures in univariate analyses, this association was less pronounced in adjusted analyses. Our findings suggest that, once MDR-tuberculosis is identified and treated appropriately with individualized therapy based on available DST, children with the disease have a good prognosis, even in areas with a high prevalence of HIV coinfection.
Other reports of MDR-tuberculosis in children include a previous study from Cape Town of 39 children with cultureconfirmed disease; similar to the present study, treatment delay was common if an MDR index case of tuberculosis was not identified [4] . A study from Peru described 38 children treated for MDR-tuberculosis, 28 of whom had confirmed disease, and also found considerable delay in the initiation of appropriate therapy [5] . A study from New York of 20 children treated for MDR-tuberculosis (6 of whom had culture-confirmed disease), demonstrated good outcomes and minimal toxicity [6] . A recent case series of 13 children with culture-confirmed MDRtuberculosis from Johannesburg (54% of whom were HIVinfected) indicated high mortality of 30% [12] . Other case reports and small series have been reported from other settings [7] [8] [9] [10] [11] [13] [14] [15] [16] . Despite the delay in diagnosis, severe disease at presentation, and the need for second-line medications, these studies all describe good outcomes, in dramatic contrast to adult MDR-tuberculosis data [2] . Reasons for this contrast are unclear. Children may have less severe and paucibacillary disease, may tolerate and adhere to medications better, may have a lower prevalence of HIV-infection, or may have a lower prevalence of concomitant pathology. Further research is required in this field.
The absence of an identified adult MDR-tuberculosis index case was strongly associated with delay in initiation of appropriate treatment in children. Of note, 16 (14.4%) children had index cases who were documented to have died, failed treatment, or undergone retreatment, indicating a high risk of MDR-tuberculosis exposure. These factors highlight the importance of careful history taking from both the child's caregiver and from health services regarding contact with adults with known MDR-tuberculosis or with known risk factors for MDR-tuberculosis.
Since we only report on children with culture-confirmed disease, our data are not representative of all children with MDR-tuberculosis, many of whom are treated on the basis of MDR-tuberculosis contact history or poor clinical response to therapy. As bacteriological yield is associated with radiological extent of disease [19] , we likely report children with more advanced disease. Since we report on children who received a diagnosis of MDR-tuberculosis by use of combined sources of surveillance (ie, laboratory and tuberculosis register sources), we do not report on only those who started therapy (which is the traditional tuberculosis treatment cohort approach). Given this conservative approach, we probably underestimate treatment success in our cohort. The long duration of treatment (a median of 6 months with a second-line injectable medication and 18 months overall) could possibly be reduced in children with less severe disease in the future, if adequate evidence from clinical studies becomes available. In our study, many children had severe disease at initiation of treatment. There was a high proportion with a positive smear, and nearly half had cavities, severe bronchopneumonic changes, or a miliary opacification on a chest radiograph. Young children are traditionally considered to have paucibacillary tuberculosis, and as they generally have a poor tussive force, they are considered to pose a low infection risk. However, our data indicate that children with culture-confirmed MDRtuberculosis frequently have severe disease, are somewhat older than those with drug-susceptible tuberculosis [22, 39] , and, coupled with high rates of smear positivity, may prove a greater risk for tuberculosis transmission than previously thought. Infection control should be an important consideration in the management of children with MDR-tuberculosis.
This retrospective study has limitations, including reliance on routine data. We did not have systematic data regarding adverse effects, and the tolerability of multiple medications, frequently unpalatable, was not systematically assessed. Although all samples were confirmed to be MDR-tuberculosis, DST for second-line drugs was not routinely completed during the study period. We have reported the second-line DST results that were available, but because of inconsistent testing and significant bias in completion of DST, we are unable to draw meaningful conclusions. Finally, although treatment outcomes were good, we do not comment on morbidity as a result of MDR-tuberculosis disease and treatment. All of these aspects need assessment in future prospective studies.
In conclusion, although South African children with confirmed MDR-tuberculosis often present with severe disease and have a high frequency of HIV infection, excellent treatment outcomes can be achieved in high-burden settings with individualized clinical care under standard programmatic conditions. 
Notes
